Skip to Main Content

New versions of Bluebird Bio’s gene therapy for inherited blood disorders yielded significant benefits for patients, according to updated results from ongoing clinical trials released Friday.

But whether those benefits will endure for the patients with those conditions, beta-thalassemia and sickle cell disease, remains an open question, even as the Cambridge-based biotech prepares to submit for its first marketing approval in Europe by the end of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • So the Trump FDA is refusing and resisting putting this encouraging new treatment and possible cure to sickle cell disease on fast track review and approval because and why? Obvious answer with Trump & Pence and McConnell and Ryan…..what demographic is impacted by sickle cell disease? African-Americans!

Comments are closed.